{
    "name": "enasidenib",
    "comment": "Rx",
    "other_names": [
        "Idhifa"
    ],
    "classes": [
        "IDH2 Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/idhifa-enasidenib-1000160",
    "pregnancy": {
        "common": [
            "Based on animal embryofetal toxicity studies, fetal harm may occur when administered to pregnant females",
            "No data available on use in pregnant females to inform a drug-associated risk of major birth defects and miscarriage"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Oral administration of enasidenib to pregnant rats and rabbits during organogenesis was associated with embryofetal mortality and alterations to growth starting at 0.1 times the steady state clinical exposure based on the AUC at the recommended human dosage",
                    "If used during pregnancy, or if patient becomes pregnant while taking this drug, advise of the potential risk to a fetus"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on findings in animals, fertility may be impaired in females and males of reproductive potential",
                    "Unknown whether effects on fertility are reversible"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Avoid becoming pregnant while receiving enasidenib",
                    "Use effective contraception during treatment with enasidenib and for at least 2 month after the last dose",
                    "Coadministration of enasidenib may increase or decrease the concentrations of combined hormonal contraceptives; the clinical significance is unknown at this time"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of enasidenib or its metabolites in human milk, effects on the breastfed infants, or effects on milk production",
            "Advise women not to breastfeed during treatment with enasidenib and for at least 2 months after last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Differentiation syndrome",
                    "description": [
                        "In the clinical trial, 14% of patients treated with enasidenib experienced symptoms of differentiation syndrome, which can be fatal if not treated",
                        "Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multiorgan dysfunction",
                        "Differentiation syndrome has been observed with and without concomitant hyperleukocytosis, as early as 1 day and at up to 5 months after initiating enasidenib",
                        "If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution",
                        "Taper corticosteroids only after resolution of symptoms; differentiation syndrome symptoms may recur with premature discontinuation of corticosteroids",
                        "If severe pulmonary symptoms requiring intubation or ventilator support and/or renal dysfunction persist for >48 hr after initiation of corticosteroids, interrupt enasidenib until signs and symptoms are no longer severe",
                        "Hospitalization for close observation and monitoring of patients with pulmonary and/or renal manifestation is recommended"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Differentiation syndrome reported, which can be fatal if not treated",
                "Based on animal embryofetal toxicity studies, can cause embryofetal harm when administered to pregnant women "
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "OATP1B1, OATP1B3, and BCRP substrates",
                        "Enasidenib is an OATP1B1, OATP1B3, and BCRP inhibitor",
                        "Coadministration with OATP1B1, OATP1B3, and BCRP substrates will increase effects and toxicities of these substrates",
                        "Decrease dose of OATP1B1, OATP1B3, and BCRP substrate(s) as recommended in respective prescribing information, and as clinically indicated",
                        "P-gp substrates",
                        "Enasidenib is a P-gp inhibitor",
                        "Coadministration with P-gp substrates will increase effects and toxicities of these substrates",
                        "For a sensitive P-gp substrate may lead to serious adverse reactions, decrease dose or modify dosing frequency of such a P-gp substrate and monitor for adverse reactions as recommended in respective prescribing information"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Minor",
            "interaction_with": "dienogest/estradiol valerate",
            "description": {
                "common": "enasidenib, dienogest/estradiol valerate. unknown mechanism. Minor/Significance Unknown. Coadministration of enasidenib may increase or decrease the concentrations of combined hormonal contraceptives. Clinical significance of this interaction is unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "drospirenone",
            "description": {
                "common": "enasidenib, drospirenone. unknown mechanism. Minor/Significance Unknown. Coadministration of enasidenib may increase or decrease the concentrations of combined hormonal contraceptives. Clinical significance of this interaction is unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "enasidenib, ethinylestradiol. unknown mechanism. Minor/Significance Unknown. Coadministration of enasidenib may increase or decrease the concentrations of combined hormonal contraceptives. Clinical significance of this interaction is unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levonorgestrel oral",
            "description": {
                "common": "enasidenib, levonorgestrel oral. unknown mechanism. Minor/Significance Unknown. Coadministration of enasidenib may increase or decrease the concentrations of combined hormonal contraceptives. Clinical significance of this interaction is unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate",
            "description": {
                "common": "enasidenib, levonorgestrel oral/ethinylestradiol/ferrous bisglycinate. unknown mechanism. Minor/Significance Unknown. Coadministration of enasidenib may increase or decrease the concentrations of combined hormonal contraceptives. Clinical significance of this interaction is unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Total bilirubin increased",
            "percent": "81"
        },
        {
            "name": "Calcium decreased",
            "percent": "74"
        },
        {
            "name": "Nausea",
            "percent": "50"
        },
        {
            "name": "Diarrhea",
            "percent": "43"
        },
        {
            "name": "Potassium decreased",
            "percent": "41"
        },
        {
            "name": "Vomiting",
            "percent": "34"
        },
        {
            "name": "Decreased appetite",
            "percent": "34"
        },
        {
            "name": "Phosphorus decreased",
            "percent": "27"
        },
        {
            "name": "Differentiation syndrome",
            "percent": "14"
        },
        {
            "name": "Noninfectious leukocytosis",
            "percent": "12"
        },
        {
            "name": "Dysgeusia",
            "percent": "12"
        },
        {
            "name": "Total bilirubin increased",
            "percent": "15"
        },
        {
            "name": "Potassium decreased",
            "percent": "15"
        },
        {
            "name": "Pulmonary edema",
            "percent": "10"
        },
        {
            "name": "Acute respiratory distress syndrome",
            "percent": "10"
        },
        {
            "name": "Tumor lysis syndrome",
            "percent": "6"
        },
        {
            "name": "Diarrhea",
            "percent": "8"
        },
        {
            "name": "Calcium decreased",
            "percent": "8"
        },
        {
            "name": "Phosphorus decreased",
            "percent": "8"
        },
        {
            "name": "Differentiation syndrome",
            "percent": "7"
        },
        {
            "name": "Tumor lysis syndrome",
            "percent": "6"
        },
        {
            "name": "Noninfectious leukocytosis",
            "percent": "6"
        },
        {
            "name": "Nausea",
            "percent": "5"
        },
        {
            "name": "Decreased appetite",
            "percent": "4"
        },
        {
            "name": "Vomiting",
            "percent": "2"
        }
    ]
}